Bristol Myers Squibb stock heads into the open after a 1.9 percent drop
Published on 09/09/2026 at 07:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 8, 2026, Bristol Myers Squibb stock ended the New York session at USD 64.69 on its primary US listing, down 3.2 percent from the previous day. The share price sat roughly 14 percent below a cited valuation reference and remained well off the upper end of its 52-week range, while the S&P 500 slipped 0.4 percent the same day per market data.
September 8, 2026 in numbers
Bristol Myers Squibb Inc. (ISIN US0897961004) saw its stock close at USD 64.69 in New York on September 8, 2026, after a prior session close of about USD 66.82, marking a decline of slightly more than 3 percent in that latest session. According to analysis from GuruFocus, the move left the shares trading at USD 64.69, described there as modestly above a proprietary fair-value estimate, underlining that the stock remains below elevated levels seen earlier in the year. Over the same session, the S&P 500 index declined 0.4 percent to 7,718.41, indicating that Bristol Myers Squibb underperformed the broader market in that period.
Intraday trading on September 8, 2026 showed Bristol Myers Squibb fluctuating within a range around the mid-USD 60s, with the close near the low end of that band, while total volume stayed within recent averages, signaling ongoing investor activity despite the price pressure. Recent historical data compiled by Forbes show previous closes such as USD 66.82 on September 4, 2026, highlighting that the latest drop has widened the short-term pullback from levels above USD 67 seen earlier in the week.
Trial news shapes today’s focus
Today, attention around Bristol Myers Squibb is likely to center on its cell therapy pipeline after the company announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of the potential first-in-class GPRC5D-directed CAR T cell therapy, arlocabtagene autoleucel. As Las Vegas Sun reported on September 8, 2026, the trial met its primary endpoint in patients with relapsed or refractory multiple myeloma, providing new clinical evidence that could influence sentiment toward the company’s oncology franchise. A separate report from Reuters on September 8, 2026 also highlighted successful mid-stage results for the same blood cancer cell therapy, reinforcing the significance of the data for investors tracking the company’s experimental treatments.
Against this backdrop, broader market conditions remain a relevant factor heading into the open. As Zacks noted in its September 8, 2026 wrap, the S&P 500 index closed down 0.4 percent, reflecting ongoing pressure from macro drivers including higher energy prices and sector-specific concerns. These broader moves frame today’s session for Bristol Myers Squibb, with investors weighing the company’s new trial data against a generally more cautious equity backdrop in the large-cap health care space.
